Title: Short Term Effect of Intravitreal Injection of Bevacizumab on Intraocular Pressure
Authors: Parvez Ahmad Bhat, Arsalan Un Nisa, Shiraz Ahmad Bhat, Rameez Ahmad Ganie, Athar Fayaz Shah
DOI: https://dx.doi.org/10.18535/jmscr/v8i7.44
Abstract
Purpose: To study the short-term effect of intravitreal injection of bevacizumab on intraocular pressure (IOP).
Methods: Total of 180 patients were included in this study who received intravitreal injection of bevacizumab (1.25mg/0.05ml;Avastin) for various intraocular conditions like macular edema associated with diabetic retinopathy, wet –age related macular degeneration and macular edema in retinal venous occlusions. IOP was measured at just before giving injection and then at 5minutes, 10 minutes, 30 minutes, 60 minutes, 24 hours, day 3 and day 7 post injection using Goldman Applanation tonometry.
Results: Mean pre-injection IOP was 14.41±3.64 mmHg which rose to mean IOP of 39.08±9.54 mmHg (p value-0.000) at 5 minutes after giving injection. Mean IOP was 32.79±7.66 mmHg (p value-0.000) at 10 minutes, 27.16±6.41 mmHg (p value-0.000) at 30 minutes, 23.26±5.25mmHg (p value 0.000) at 60 minutes, 14.78±3.62 mmHg (p value-0.013) at 24 hours, 14.6±3.59 mmHg (p value -0.164) at day 3 and 14.53±3.55 mmHg (p value-0.327) at day 7 after giving the injection.
Conclusion: we found that IOP can quite high just after giving intravitreal injection which usually comes down to normal range within an hour after injection. so there is no need to give antiglaucoma medication like oral acetazolamide or topical drops to control IOP in these patients.
References
- Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreal injections: A comprehensive review. Retina 2004;24:676-698.
- Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF inhibition study in ocular neovascularisation clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816
- Hariprasad SM, Shah GK, Blinder KJ. Short-term intraocular pressure changes following intravitreal pegaptanib injections. Am J Ophthalmol 2006; 141:200-201
- Falkenstein LA, Cheng L, Freeman WR. Changes of intraocular pressure following intravitreal injection of bevacizumab. Retina 2007;27:1044-1047.
- Benz MS, Albini TA, Holz ER, et al.short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 2006;113:1174-1178.
- Judy E Kim, Anand v Mantravadi, Elizabeth Y Hur, Douglas J Covert et al.short-term intraocular changes after intravitreal injection of anti vascular endothelial growth factor agents.Am J Ophthalmol 2008;146:929-934.
- Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. immediate intraocular pressure changes following intravitreal injection of triamcinolone, pegaptanib, and bevacizumab. Eye 2009;157:874-876.
- Kotliar K, Maier M, Bauer S, Feucht N, Lohman C, Lanzl I. Effect of intravitreal injection and volume changes on intraocular pressure. Clinical results and biomechanical model. Acta Ophthalmol Scand 2007;85:777-781.